University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
Roche announced positive Phase III MAJESTY trial results showing Gazyva achieved significantly higher complete remission rates at two years versus tacrolimus in primary membranous nephropathy, with no new safety signals identified.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07468526 |
An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria |
NOT_YET_RECRUITING | PHASE3 |
| NCT07468513 |
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. |
RECRUITING | PHASE4 |
| NCT07434180 |
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary |
NOT_YET_RECRUITING | PHASE2 |
| NCT07416292 |
ListenFuture-Listening for Their Future: Deaf and Hard-of-Hearing Adolescents |
RECRUITING | |
| NCT07384702 |
Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia |
NOT_YET_RECRUITING | PHASE2 |
| NCT07337382 |
The Optimising Isolation, Quarantine and Distancing Study for COVID-19 |
ACTIVE_NOT_RECRUITING | |
| NCT07293455 |
Evaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia |
NOT_YET_RECRUITING | NA |
| NCT07253688 |
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus |
RECRUITING | PHASE3 |
| NCT07225465 |
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin |
NOT_YET_RECRUITING | PHASE2 |
| NCT07145736 |
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases |
RECRUITING | PHASE4 |
